Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: The Women's Health Initiative

Cancer

Volumn 119, Issue 8, 2013, Pages 1562-1569

  Gamba, Christina A ^a   Swetter, Susan M ^a,b   Stefanick, Marcia L ^a   Kubo, Jessica ^a   Desai, Manisha ^a   Spaunhurst, Katrina M ^c   Sinha, Animesh A ^d   Asgari, Maryam M ^e   Sturgeon, Susan ^f   Tang, Jean Y ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e DIVISION OF RESEARCH   (United States)

^f UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

anti inflammatory agents; aspirin; female; incidence; melanoma; nonsteroidal

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; CUTANEOUS MELANOMA; DRUG EFFICACY; DRUG INDICATION; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; SELF REPORT; SUN EXPOSURE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MELANOMA; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SKIN NEOPLASMS; UNITED STATES;

EID: 84876032294     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27817     Document Type: Article

References (33)

1. Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol. 2011; 65 (5 suppl 1): S17-S25.e3.
2. Bordeaux JS, Lu KQ, Cooper KD,. Melanoma: prevention and early detection. Semin Oncol. 2007; 34: 460-466.
3. Tian W, Zhao Y, Liu S, Li X,. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev. 2010; 19: 288-298.
4. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of 5 randomised trials. Lancet. 2010; 376: 1741-1750.
5. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003; 63: 6096-6101.
6. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G,. Aspirin, salicylates, and cancer. Lancet. 2009; 373: 1301-1309.
7. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN,. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005; 23: 254-266.
8. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T,. COX-2 expression in malignant melanoma: a novel prognostic marker? Melanoma Res. 2009; 19: 8-16.
9. Kuzbicki L, Sarnecka A, Chwirot BW,. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res. 2006; 16: 29-36.
10. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB,. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004; 23: 9247-9258.
11. Harris RE, Beebe-Donk J, Namboodiri KK,. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep. 2001; 8: 655-657.
12. Joosse A, Koomen ER, Casparie MK, Herings RM, Guchelaar HJ, Nijsten T,. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol. 2009; 129: 2620-2627.
13. Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS,. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol. 2011; 131: 1460-1468.
14. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294: 47-55.
15. Asgari MM, Maruti SS, White E,. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst. 2008; 100: 967-971.
16. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE,. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007; 99: 608-615.
17. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998; 19: 61-109.
18. Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006; 166: 1907-1914.
19. Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003; 13 (9 suppl): S18-S77.
20. Millen AE, Pettinger M, Freudenheim JL, et al. Incident invasive breast cancer, geographic location of residence, and reported average time spent outside. Cancer Epidemiol Biomarkers Prev. 2009; 18: 495-507.
21. National Institutes of Health. Women's Health Initiative. Form 44-Current Medications. Available at: https://cleo.whi.org/studydoc/Central%20Forms/F044. pdf. Accessed July 28, 2012.
22. DeLancey JO, Hannan LM, Gapstur SM, Thun MJ,. Cigarette smoking and the risk of incident and fatal melanoma in a large prospective cohort study. Cancer Causes Control. 2011; 22: 937-942.
23. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005; 41: 45-60.
24. Kricker A, Armstrong BK, Goumas C, et al. Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control. 2007; 18: 295-304.
25. Tang JY, Fu T, Leblanc E, et al. Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the Women's Health Initiative randomized controlled trial. J Clin Oncol. 2011; 29: 3078-3084.
26. Bardia A, Ebbert JO, Vierkant RA, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007; 99: 881-889.
27. Vad NM, Yount G, Moridani MY,. Biochemical mechanism of acetylsalicylic acid (aspirin) selective toxicity toward melanoma cell lines. Melanoma Res. 2008; 18: 386-399.
28. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379: 1602-1612.
29. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW,. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011; 377: 31-41.
30. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011; 378: 2081-2087.
31. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009; 10: 501-507.
32. Parr CL, Hjartaker A, Laake P, Lund E, Veierod MB,. Recall bias in melanoma risk factors and measurement error effects: a nested case-control study within the Norwegian Women and Cancer Study. Am J Epidemiol. 2009; 169: 257-266.
33. Gefeller O,. Invited commentary: recall bias in melanoma-much ado about almost nothing? Am J Epidemiol. 2009; 169: 267-270; discussion 271-272.